<span item_type="fundamental" item_id="5769a32fceb952d69e20fc2db54dbdf9" counter_id="ST/US/TLPH" env="prod"></span><span item_type="announcement" item_id="582074109066543873" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 1 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.11, meeting the estimate of USD -0.11.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -3.503 M.</p><p></p><h3>Cash and Investments</h3><ul><li>Cash and investments at September 30, 2025, were $21.3 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1427925/000143774925034446/ex_886199.htm"></span></li></ul><h3>Operating Costs and Expenses</h3><ul><li>Combined R&amp;D and SG&amp;A expenses for Q3 2025 totaled $3.4 million, down from $3.7 million in Q3 2024. Excluding non-cash stock-based compensation, these amounts were $3.3 million for Q3 2025, compared to $3.5 million for Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1427925/000143774925034446/ex_886199.htm"></span></li></ul><h3>Net Loss</h3><ul><li>Net loss from continuing operations for Q3 2025 was $4.4 million, compared to $3.4 million in Q3 2024, primarily due to an increase in the fair value of the Company’s warrant liability.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1427925/000143774925034446/ex_886199.htm"></span></li><li>Net loss attributable to common shareholders for Q3 2025 was $4.4 million, or $0.11 per basic and diluted share, compared to a net loss of $3.4 million, or $0.13 per basic and diluted share, for Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1427925/000143774925034446/ex_886199.htm"></span></li></ul><h3>Total Assets and Liabilities</h3><ul><li>Total assets as of September 30, 2025, were $30.7 million, compared to $18.2 million as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1427925/000143774925034446/ex_886199.htm"></span></li><li>Total liabilities as of September 30, 2025, were $11.6 million, compared to $10.2 million as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1427925/000143774925034446/ex_886199.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Talphera expects cash operating expenses, excluding stock-based compensation, to be in the range of $14 million to $15 million in 2025, a reduction from the previously provided range of $16 million to $17 million, with the difference expected to be realized in the first quarter of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1427925/000143774925034446/ex_886199.htm"></span></li><li>The company anticipates sufficient cash through a potential PMA approval of Niyad in late 2026, supported by current cash balance and conditional future tranches from previous financings.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1427925/000143774925034446/ex_886199.htm"></span></li><li>The NEPHRO study is expected to complete enrollment in the first half of 2026, with four new target profile sites to be activated in Q4 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1427925/000143774925034446/ex_886199.htm"></span></li></ul>

Talphera | 8-K: FY2025 Q3 Revenue: USD 1 K